Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer
…, L Adam, A Kamat, A Siefker-Radtke, C Dinney - Cancer and Metastasis …, 2009 - Springer
Epithelial-to-mesenchymal transition (EMT) is a process that plays essential roles in
development and wound healing that is characterized by loss of homotypic adhesion and cell …
development and wound healing that is characterized by loss of homotypic adhesion and cell …
[PDF][PDF] Focus on bladder cancer
… C: Histologic map of cystectomy showing the distribution of preneoplastic in situ lesions
and invasive cancer. The distribution of allelic loss in the bladder mucosa is outlined by the …
and invasive cancer. The distribution of allelic loss in the bladder mucosa is outlined by the …
Micropapillary bladder cancer: a review of the University of Texas MD Anderson Cancer Center experience with 100 consecutive patients
AM Kamat, CPN Dinney, JR Gee, HB Grossman… - Cancer, 2007 - Wiley Online Library
BACKGROUND Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma.
To improve understanding of this disease, the authors performed a retrospective review of …
To improve understanding of this disease, the authors performed a retrospective review of …
[PDF][PDF] Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy
…, A Siefker-Radtke, B Czerniak, CPN Dinney… - Cancer cell, 2014 - cell.com
Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely
variable clinical outcomes and responses to conventional chemotherapy. We discovered …
variable clinical outcomes and responses to conventional chemotherapy. We discovered …
[HTML][HTML] A consensus molecular classification of muscle-invasive bladder cancer
Background Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with
heterogeneous clinical outcomes. Several molecular classifications have been proposed, but …
heterogeneous clinical outcomes. Several molecular classifications have been proposed, but …
Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
…, BY Eve, DJ Hicklin, R Radinsky, CPN Dinney - Clinical Cancer …, 1999 - AACR
… 45C for 45 min. The slides were washed with 2 × SSC three times for 2 min each time at
45C. The samples were then incubated with avidin labeled with phosphatase for 30 min at 45C, …
45C. The samples were then incubated with avidin labeled with phosphatase for 30 min at 45C, …
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci
We conducted a multi-stage, genome-wide association study of bladder cancer with a
primary scan of 591,637 SNPs in 3,532 affected individuals (cases) and 5,120 controls of …
primary scan of 591,637 SNPs in 3,532 affected individuals (cases) and 5,120 controls of …
Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer
…, M Bar-Eli, R Radinsky, CA Pettaway, CPN Dinney - Clinical Cancer …, 2000 - AACR
… The reverse transcription reaction was performed at 42C for 50 min. PCR was performed
with 40 cycles of denaturation (94C for 1.5 min), annealing (58C for 45 s),and extension (72C …
with 40 cycles of denaturation (94C for 1.5 min), annealing (58C for 45 s),and extension (72C …
Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study
…, J Tostain, W Artibani, CP Dinney… - Journal of Clinical …, 2004 - ascopubs.org
Purpose To evaluate ability of the University of California Los Angeles Integrated Staging
System (UISS) to stratify patients with localized and metastatic renal cell carcinoma (RCC) into …
System (UISS) to stratify patients with localized and metastatic renal cell carcinoma (RCC) into …
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
…, Y Wang, J Chen, J Zhang, A Futreal, C Dinney… - Nature medicine, 2020 - nature.com
Immune checkpoint therapy is being tested in the neoadjuvant setting for patients with localized
urothelial carcinoma 1 , 2 , with one study reporting data in cisplatin-ineligible patients …
urothelial carcinoma 1 , 2 , with one study reporting data in cisplatin-ineligible patients …